MNMT yields 52631.58% · ABBV yields 3.06%● Live data
📍 MNMT pulled ahead of the other in Year 1
Combined, MNMT + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MNMT + ABBV for your $10,000?
Motivating the Masses, Inc. provides professional development and coaching services to small businesses and entrepreneurs in the United States. It operates through two segments, Business and Personal. The company offers personal and business coaching programs through a package of books and DVDs; and training and development programs through local and national seminars, on-site employee training, public and private speaking engagements, and customized life-coaching programs. Its services include Global Leadership Program that offers group coaching services; Executive Coaching services; Business Academy training programs for entrepreneurs to grow their brand; Keynotes/Speaking services at industry events and at private gatherings; Speak And Write to Make Millions, a live training program, which teaches attendees how to speak powerfully and to write best sellers; and Speakers Vault, a comprehensive on-line training program for speakers. The company's services also comprise Breakthrough the Retreat, an intensive program for executives and entrepreneurs ready; Abundance Now, a 12-part online course; Transformational Coaching services for personal development; and Motivating the Teen Spirit, an advanced life skills training for teens and their parents, as well as online modules, such as 28 Days To Results and No Matter What. Motivating the Masses, Inc. was founded in 1998 and is headquartered in Carlsbad, California.
Full MNMT Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.